WT6
MCID: WLM011
MIFTS: 19

Wilms Tumor 6 (WT6) malady

Categories: Genetic diseases, Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Wilms Tumor 6

Aliases & Descriptions for Wilms Tumor 6:

Name: Wilms Tumor 6 54 66
Wilms Tumor 6, Susceptibility to 66
Susceptibility to Wilms Tumor 6 66
Wilms Tumor, Susceptibility to 66
Wt6 66

Classifications:



External Ids:

MedGen 40 CN235182
MeSH 42 D009396

Summaries for Wilms Tumor 6

UniProtKB/Swiss-Prot : 66 Wilms tumor 6: A pediatric malignancy of kidney, and the most common childhood abdominal malignancy. It is caused by the uncontrolled multiplication of renal stem, stromal, and epithelial cells.

MalaCards based summary : Wilms Tumor 6, is also known as wilms tumor 6, susceptibility to. An important gene associated with Wilms Tumor 6 is REST (RE1 Silencing Transcription Factor). The drugs Doxorubicin and Cyclosporine have been mentioned in the context of this disorder. Affiliated tissues include kidney.

Related Diseases for Wilms Tumor 6

Symptoms & Phenotypes for Wilms Tumor 6

Clinical features from OMIM:

616806

Drugs & Therapeutics for Wilms Tumor 6

Drugs for Wilms Tumor 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Cyclosporine Approved, Investigational, Vet_approved Phase 3 79217-60-0, 59865-13-3 5284373 6435893
3
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
4
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
5
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
6
Cytarabine Approved, Investigational Phase 2, Phase 3, Phase 1 147-94-4 6253
7
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
9
Mycophenolic acid Approved Phase 3 24280-93-1 446541
10
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
11
Morphine Approved, Investigational Phase 3 57-27-2 5288826
12
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
13
Histamine Approved, Investigational Phase 3,Phase 1,Phase 2 75614-87-8, 51-45-6 774
14
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
15
Lenograstim Approved Phase 3,Phase 1 135968-09-1
16
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
17
Cyproheptadine Approved Phase 3 129-03-3 2913
18
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
19 Anti-Infective Agents Phase 3,Phase 2,Phase 1
20 Liver Extracts Phase 3,Phase 2,Phase 1
21
Histamine Phosphate Phase 3,Phase 1,Phase 2 51-74-1 65513
22 Alkylating Agents Phase 3,Phase 2,Phase 1
23 Adjuvants, Immunologic Phase 3,Phase 1,Phase 2
24 Gastrointestinal Agents Phase 3,Phase 1,Phase 2
25 Neurotransmitter Agents Phase 3,Phase 1,Phase 2
26 Gemtuzumab Phase 2, Phase 3
27 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
28 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
29 Histamine Antagonists Phase 3,Phase 1,Phase 2
30 Histamine H1 Antagonists Phase 3,Phase 1,Phase 2
31 Dermatologic Agents Phase 3,Phase 1,Phase 2
32 Anti-Allergic Agents Phase 3,Phase 1,Phase 2
33 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
34 Etoposide phosphate Phase 3,Phase 2,Phase 1
35 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
36 Antifungal Agents Phase 3,Phase 2,Phase 1
37 Antilymphocyte Serum Phase 3
38 Antimetabolites Phase 3,Phase 2,Phase 1
39 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
40 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
41 Antimitotic Agents Phase 3,Phase 2,Phase 1
42 Antirheumatic Agents Phase 3,Phase 1,Phase 2
43 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
45 Calcineurin Inhibitors Phase 3
46 Antipruritics Phase 3,Phase 1,Phase 2
47
Serotonin Phase 3 50-67-9 5202
48 Serotonin Agents Phase 3
49 Serotonin Antagonists Phase 3
50
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622

Interventional clinical trials:

(show top 50) (show all 61)
id Name Status NCT ID Phase
1 Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed NCT00002611 Phase 3
2 Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) Completed NCT00909168 Phase 2, Phase 3
3 Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk Completed NCT00860639 Phase 3
4 HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk Completed NCT02461121 Phase 3
5 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Active, not recruiting NCT00379340 Phase 3
6 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
7 Dendritic Cell Vaccination for Patients With Solid Tumors Unknown status NCT01291420 Phase 1, Phase 2
8 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
9 Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy Completed NCT01819558 Phase 1, Phase 2
10 Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers Completed NCT00488592 Phase 2
11 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Completed NCT00923910 Phase 1, Phase 2
12 Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Completed NCT00002466 Phase 2
13 To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Completed NCT01222780 Phase 1, Phase 2
14 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Completed NCT00335556 Phase 2
15 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
16 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2
17 WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study Recruiting NCT01621724 Phase 1, Phase 2
18 Autologous Dendritic Cell Vaccination in Mesothelioma Recruiting NCT02649829 Phase 1, Phase 2
19 DC Vaccination for Post-remission Therapy in AML Recruiting NCT02405338 Phase 1, Phase 2
20 Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients Recruiting NCT02649582 Phase 1, Phase 2
21 Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT Recruiting NCT02472691 Phase 2
22 Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Recruiting NCT02574728 Phase 2
23 Study of Biomarker-Based Treatment of Acute Myeloid Leukemia Recruiting NCT03013998 Phase 1, Phase 2
24 Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Active, not recruiting NCT01266083 Phase 2
25 Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy Active, not recruiting NCT01265433 Phase 2
26 Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134 Active, not recruiting NCT01890980 Phase 2
27 Laboratory-Treated (Central Memory/Naïve) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia Not yet recruiting NCT02770820 Phase 1, Phase 2
28 A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy Not yet recruiting NCT03149003 Phase 2
29 WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation Suspended NCT01334060 Phase 2
30 Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer Terminated NCT01220128 Phase 2
31 Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission Completed NCT00834002 Phase 1
32 Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients Completed NCT01169584 Phase 1
33 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma Completed NCT00398138 Phase 1
34 Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors Completed NCT00020150 Phase 1
35 Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides Completed NCT01598454 Phase 1
36 Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors Completed NCT00003597 Phase 1
37 CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Recruiting NCT01995708 Phase 1
38 A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer Recruiting NCT02737787 Phase 1
39 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Recruiting NCT02498665 Phase 1
40 A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Recruiting NCT02536183 Phase 1
41 Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies Recruiting NCT02392793 Phase 1
42 Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Recruiting NCT02390843 Phase 1
43 Administration of Donor MultiTAA-Specific T Cells for ALL Recruiting NCT02475707 Phase 1
44 Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) Recruiting NCT02494167 Phase 1
45 HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors Recruiting NCT00931931 Phase 1
46 Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors Recruiting NCT02789228 Phase 1
47 Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation Active, not recruiting NCT00620633 Phase 1
48 Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/ Active, not recruiting NCT00562640 Phase 1
49 Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting NCT01331135 Phase 1
50 Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML Enrolling by invitation NCT02750995 Phase 1

Search NIH Clinical Center for Wilms Tumor 6

Genetic Tests for Wilms Tumor 6

Anatomical Context for Wilms Tumor 6

MalaCards organs/tissues related to Wilms Tumor 6:

39
Kidney

Publications for Wilms Tumor 6

Variations for Wilms Tumor 6

UniProtKB/Swiss-Prot genetic disease variations for Wilms Tumor 6:

66
id Symbol AA change Variation ID SNP ID
1 REST p.Arg160Pro VAR_076333
2 REST p.Asn290Tyr VAR_076334
3 REST p.His322Arg VAR_076335 rs869025312
4 REST p.His412Gln VAR_076336

ClinVar genetic disease variations for Wilms Tumor 6:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 REST NM_005612.4(REST): c.831_832delAT (p.Cys278Trpfs) deletion risk factor rs869025310 GRCh38 Chromosome 4, 56911469: 56911470
2 REST NM_005612.4(REST): c.773_776delTGAG (p.Val258Alafs) deletion risk factor rs869025311 GRCh38 Chromosome 4, 56911411: 56911414
3 REST NM_005612.4(REST): c.965A> G (p.His322Arg) single nucleotide variant risk factor rs869025312 GRCh38 Chromosome 4, 56919853: 56919853

Expression for Wilms Tumor 6

Search GEO for disease gene expression data for Wilms Tumor 6.

Pathways for Wilms Tumor 6

GO Terms for Wilms Tumor 6

Sources for Wilms Tumor 6

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....